Dr. Steven Macina, DO
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 348
Licensed in California since 1994, according to the Osteopathic Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
CA license 20A6625 (first issued 1994; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- West Anaheim Medical Center Anaheim, CA
- Huntington Beach Hospital Huntington Beach, CA
- Anaheim Community Hospital, LLC Anaheim, CA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 348
- Services billed
- 3,270
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,047 | 140 |
| Established patient office or other outpatient visit, 20-29 minutes | 947 | 167 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 362 | 51 |
| Psychotherapy with evaluation and management visit, 30 minutes | 348 | 50 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | 163 | 104 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 45 | 35 |
| Psychiatric diagnostic evaluation with medical services | 25 | 25 |
| Hospital discharge day management, 30 minutes or less | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 11 payments worth $480 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $231 |
|---|---|
| Neurocrine Biosciences, Inc. | $129 |
| Teva Pharmaceuticals USA, Inc. | $120 |
| Food and Beverage | $480 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 29 industry-funded studies in 2025, from 9 companies. The companies reported $2,689,945 in research payments for these studies, mostly to the institutions running them.
- ITI-007-452
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
AbbVie Inc. · Terminated · NCT05443724 - ITI-1284-101
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended…
Teva Pharmaceuticals USA, Inc. - An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309 - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
E.r. Squibb & Sons, L.l.c. - A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
E.r. Squibb & Sons, L.l.c. - ITI-1284-201
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - TV50717-CNS-40223
Teva Pharmaceuticals USA, Inc. - A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.